Related references
Note: Only part of the references are listed.Insulin-Like Growth Factors Are Key Regulators of T Helper 17 Regulatory T Cell Balance in Autoimmunity
Daniel DiToro et al.
IMMUNITY (2020)
The effect of combined functional training on BDNF, IGF-1, and their association with health-related fitness in the multiple sclerosis women
Elnaz Abbaspoor et al.
GROWTH HORMONE & IGF RESEARCH (2020)
Systemic Effects by Intrathecal Administration of Triamcinolone Acetonide in Patients With Multiple Sclerosis
Andreas Hoeflich et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
PAPP-A activity is increased in cerebrospinal fluid from patients with diabetic polyneuropathy and correlates with peripheral nerve impairment
M. Kallestrup et al.
GROWTH HORMONE & IGF RESEARCH (2019)
A common variant of the pregnancy-associated plasma protein-A (PAPPA) gene encodes a protein with reduced proteolytic activity towards IGF-binding proteins
Jane Alro Botkjaer et al.
SCIENTIFIC REPORTS (2019)
PAPP-A and cancer
Cheryl A. Conover et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2018)
Multiple Sclerosis
Daniel S. Reich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Serum insulin-like growth factor 1 (IGF-1) in multiple sclerosis: relation to cognitive impairment and fatigue
Rania S. Nageeb et al.
EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY (2018)
Insulin-Like Growth Factor Bioactivity, Stanniocalcin-2, Pregnancy-Associated Plasma Protein-A, and IGF-Binding Protein-4 in Pleural Fluid and Serum From Patients With Pulmonary Disease
Ulrick Skipper Espelund et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
One level up: abnormal proteolytic regulation of IGF activity plays a role in human pathophysiology
Jesus Argente et al.
EMBO MOLECULAR MEDICINE (2017)
Spasticity in multiple sclerosis: Contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions
Robert Patejdl et al.
AUTOIMMUNITY REVIEWS (2017)
Managing Disability in Progressive Multiple Sclerosis
Divyanshu Dubey et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2016)
Quantitative Western ligand blotting reveals common patterns and differential features of IGFBP-fingerprints in domestic ruminant breeds and species
Elisa Wirthgen et al.
GROWTH HORMONE & IGF RESEARCH (2016)
Effects of intrathecal triamincinolone-acetonide treatment in MS patients with therapy-resistant spasticity
F. Kamin et al.
SPINAL CORD (2015)
Reference Intervals for Insulin-like Growth Factor-1 (IGF-I) From Birth to Senescence: Results From a Multicenter Study Using a New Automated Chemiluminescence IGF-I Immunoassay Conforming to Recent International Recommendations
Martin Bidlingmaier et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Age- and Sex-Specific Reference Intervals Across Life Span for Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 Ratio Measured by New Automated Chemiluminescence Assays
Nele Friedrich et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
The plasticity of human Treg and Th17 cells and its role in autoimmunity
Markus Kleinewietfeld et al.
SEMINARS IN IMMUNOLOGY (2013)
Management of Spasticity in Progressive Multiple Sclerosis: Efficacy of Repeated Intrathecal Triamcinolone Acetonide Administration
Mazen Abu-Mugheisib et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients
R. Lanzillo et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
Progesterone and dexamethasone differentially regulate the IGF-system in glial cells
Daniel Chesik et al.
NEUROSCIENCE LETTERS (2010)
GH, IGF-I, IGFBP-3 and IGFBP-2 in cerebrospinal fluid of infants, during puberty and in adults
E. Heinze et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2009)
Changes within the growth hormone/insulin-like growth factor I/IGF binding protein axis during critical illness
Dieter Mesotten et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2006)
Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men
T Münzer et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2006)
Growth hormone and insulin growth factor-I levels in plasma and cerebrospinal fluid of patients with multiple sclerosis
Z Poljakovic et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2006)
Targeted expression of IGF-1 in the central nervous system fails to protect mice from experimental autoimmune encephalomyelitis
S Genoud et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
Cerebrospinal fluid insulin-like growth factor-1, insulin growth factor binding protein-2 or nitric oxide are not increased in MS or ALS
T Pirttilä et al.
ACTA NEUROLOGICA SCANDINAVICA (2004)
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain
DJ Cua et al.
NATURE (2003)
Pregnancy-associated plasma protein-A is involved in insulin-like growth factor binding protein-2 (IGFBP-2) proteolytic degradation in bovine and porcine preovulatory follicles: Identification of cleavage site and characterization of IGFBP-2 degradation
P Monget et al.
BIOLOGY OF REPRODUCTION (2003)
Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination
B Cannella et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
